2005 Annual Meeting | Evaluation and Management of Autonomic Disorders

Date Tuesday 04/12/05

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) William P. Cheshire, Jr., MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Upon completion:
Participants should be able to enhance their ability to formulate a differential diagnosis, organize a workup, and offer a treatment plan for patients with common and less common varieties of autonomic dysfunction.

CME Available No CME available

Program Level Introductory

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
02:15 PM - 02:25 PM		Introduction William P. Cheshire, Jr., MD, FAAN
02:25 PM - 03:10 PM		Autonomic Neuropathies Roy L. Freeman, MD
03:10 PM - 03:55 PM		Disorders of Thermoregulation and Sweating William P. Cheshire, Jr., MD, FAAN
03:55 PM - 04:10 PM		Break
04:10 PM - 04:55 PM		Orthostatic Hypotension Thomas C. Chelimsky, MD
04:55 PM - 05:40 PM		Orthostatic Intolerance Phillip A. Low, MD, FAAN
05:40 PM - 06:00 PM		Questions and Answers

Faculty Disclosures
Roy L. Freeman, MD	Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck.
Phillip A. Low, MD, FAAN	Dr. Low has nothing to disclose.
Thomas C. Chelimsky, MD	Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Proctor & Gamble. Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Various Legal Firms. Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Various Legal Firms. Dr. Chelimsky has received stock or an ownership interest from PainSTakers, LLC. The institution of Dr. Chelimsky has received research support from NIDDK. The institution of Dr. Chelimsky has received research support from Advancing a Healthier Wisconsin.
William P. Cheshire, Jr., MD, FAAN	Dr. Cheshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for oxford university press. Dr. Cheshire has a non-compensated relationship as a Associate Editor with Clinical Autonomic Research that is relevant to AAN interests or activities.

��ɫ��

��ɫ��